FN1 and idiopathic pulmonary fibrosis: Furthermore, SGC-CBP30 reduces fibrotic hallmarks in vitro (patient-derived primary fibroblast), in vivo (bleomycin mouse model), and ex vivo (precision-cut lung slices, PCLS) in idiopathic pulmonary fibrosis models, in particular by reducing extracellular matrix protein deposition, levels of fibrotic markers such as FN1, COL1A1, and ACTA2, cell migration, and proliferation [7].